The origins of ovarian cancer

DeWeerdt, Sarah

doi:10.1038/d41586-021-03717-7

Cited by 4 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These nucleosomes circulate for a period of one to three hours before being removed by phagocytic cells and other cells. Necrosis, on the other hand, occurs when cells are damaged or stressed to the point of uncontrolled death, leading to the random and incomplete digestion of DNA ( 9 – 11 ). It has been suggested that the fragmentation profile of circulating cfDNA may reveal information about the tissue origin in cancer patients ( 11 ).…”

Section: Liquid Biopsiesmentioning

confidence: 99%

“…Necrosis, on the other hand, occurs when cells are damaged or stressed to the point of uncontrolled death, leading to the random and incomplete digestion of DNA ( 9 – 11 ). It has been suggested that the fragmentation profile of circulating cfDNA may reveal information about the tissue origin in cancer patients ( 11 ). Additionally, DNA methylation patterns are known to be tissue-specific, and thus, their analysis may allow for the determination of the origin of cf-DNA fragments.…”

Section: Liquid Biopsiesmentioning

confidence: 99%

See 1 more Smart Citation

Liquid biopsies and minimal residual disease in lymphoid malignancies

et al. 2023

View full text Add to dashboard Cite

Minimal residual disease (MRD) assessment using peripheral blood instead of bone marrow aspirate/biopsy specimen or the biopsy of the cancerous infiltrated by lymphoid malignancies is an emerging technique with enormous interest of research and technological innovation at the current time. In some lymphoid malignancies (particularly ALL), Studies have shown that MRD monitoring of the peripheral blood may be an adequate alternative to frequent BM aspirations. However, additional studies investigating the biology of liquid biopsies in ALL and its potential as an MRD marker in larger patient cohorts in treatment protocols are warranted. Despite the promising data, there are still limitations in liquid biopsies in lymphoid malignancies, such as standardization of the sample collection and processing, determination of timing and duration for liquid biopsy analysis, and definition of the biological characteristics and specificity of the techniques evaluated such as flow cytometry, molecular techniques, and next generation sequencies. The use of liquid biopsy for detection of minimal residual disease in T-cell lymphoma is still experimental but it has made significant progress in multiple myeloma for example. Recent attempt to use artificial intelligence may help simplify the algorithm for testing and may help avoid inter-observer variation and operator dependency in these highly technically demanding testing process.

show abstract

Section: Liquid Biopsiesmentioning

confidence: 99%

Section: Liquid Biopsiesmentioning

confidence: 99%

Liquid biopsies and minimal residual disease in lymphoid malignancies

et al. 2023

View full text Add to dashboard Cite

show abstract

“…HGSOC is traditional thought to development from ovarian surface epithelium (Ducie et al, 2017). Since the late 1990s, accumulating evidence indicates that HGSOC originates from fallopian tube secretory epithelial cells (DeWeerdt, 2021; Przybycin et al, 2010). However, recent studies demonstrate that both fallopian tube and ovarian surface epithelium are origin of HGSOC (Lohmussaar et al, 2020; Zhang et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12

Wang

Qin

et al. 2022

Preprint

View full text Add to dashboard Cite

Dysregulated expression of splicing factors has important roles in cancer development and progression. However, it remains a challenge to identify the cancer-specific splicing variants. Here we demonstrated that spliceosome component BUD31 is increased in ovarian cancer, and its higher expression predicts worse prognosis. We characterized the BUD31 binding motif and found that BUD31 preferentially binds exon-intron regions near splicing sites by CLIP-seq. Further analysis revealed that BUD31 inhibition results in extensive exon skipping and decreased abundance of long CDS isoforms. In particular, we identified BCL2L12, an anti-apoptotic BCL2 family member, as a functional splicing target of BUD31. BUD31 stimulates the inclusion of exon 3 to generate full-length BCL2L12 and promotes ovarian cancer progression. Knockdown of BUD31 or splice-switching antisense oligonucleotide treatment promotes exon 3 skipping and results in a truncated isoform of BCL2L12 that undergoes nonsense-mediated mRNA decay, and the cells subsequently undergo apoptosis. Our findings reveal BUD31-regulated exon inclusion as a critical factor in ovarian cancer cell survival and progression.

show abstract

Bibliography

2024

Encyclopedia of Hereditary Cancer

View full text Add to dashboard Cite

The origins of ovarian cancer

Cited by 4 publications

References 15 publications

Liquid biopsies and minimal residual disease in lymphoid malignancies

Liquid biopsies and minimal residual disease in lymphoid malignancies

Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12

Bibliography

Contact Info

Product

Resources

About